Patients at a high risk of PJI: Can we reduce the incidence of infection using dual antibiotic-loaded bone cement?

Christof Berberich1*, Jerôme Josse2 and Pablo Sanz Ruiz3,4

Abstract
Prosthetic joint infection (PJI) is one of the most devastating complications of orthopedic surgery. However, not all patients are equally at the risk of severe infection. The incidences of PJI vary with the host and surgery-related risk factors. It is now generally accepted that some important medical comorbidities may predispose the patients to a high risk of PJI. Time-consuming and invasive surgical procedures, such as revision arthroplasties, are also associated with a high incidence of PJI, presumably due to the increased risk of surgical site contamination. Effective infection-preventing strategies should begin with identifying and optimizing the patients at a high risk of infection prior to surgery. Optimizing the operating room environment and antibiotic prophylaxis are also essential strategies that help minimize the overall incidence of infection in orthopedic surgery. The ideal antibiotic prophylaxis is still under debate, and discussions have emerged about whether variations or adjustments to the standard protocol are justified in patients at a high risk of infection. This also includes evaluating the possible benefits and risks of using high-dose dual antibiotic-loaded bone cement instead of low-dose single antibiotic-loaded bone cement in arthroplasty. This review summarizes the evidence showing that the combination of two local antibiotics in bone cement exerts a strong and longer-lasting antimicrobial effect against PJI-associated pathogens. This conclusion is consistent with the preliminary clinical studies showing a low incidence of PJI in high-risk patients undergoing cemented hemiarthroplasty, cemented revision, and primary arthroplasty if dual ALBC is used. These results may encourage clinicians to consolidate this hypothesis in a wider clinical range.

Keywords: Single low-dose antibiotic-loaded bone cement, Dual high-dose antibiotic-loaded bone cement, Infection prophylaxis, Prosthetic joint infection, Risk factors for infection

Introduction
Prosthetic joint infection (PJI) remains one of the most feared complications of arthroplasty. A growing body of evidence indicates that the risk of PJI development is significantly influenced by patient- and surgery-related factors. Several important host comorbidities have been identified as important conditions that may predispose a patient to PJI. Revision arthroplasty and hemi-arthroplasty in patients with femoral neck fractures are also associated with a higher infection rate than the usual arthroplasty due to longer operative time or more debilitating host health conditions, or both.

Undoubtedly, preoperative patient optimization, strict compliance with hygiene rules in the theatre, and a perioperative antibiotic prophylaxis regimen are the main pillars of infection prevention [1, 2]. However, opposed to the PJI treatment where surgical algorithms take into consideration individual patient and pathogen factors, a similar concept of infection prevention is still lacking. A
question of particular interest is whether certain patient groups at a high risk of infection may benefit from more individualized antibiotic prophylaxis instead of a “one-size-fits-all” strategy. Indeed, some evidence supports the hypothesis that the patients at a high risk of infection may benefit from a longer-term perioperative antibiotic prophylaxis. However, its wider clinical practice remains controversial. Many surgeons decide to also use local prophylaxis with antibiotic-loaded bone cement (ALBC) as a complementary tool to systemic antibiotic prophylaxis in arthroplasty. The rationale behind this combined strategy is to create an added antimicrobial defense line in the joint space itself, without exposing the patient to the major risk of toxic side effects. Several registry studies provided evidence showing that the revision rates are reduced if systemic and local antibiotic prophylaxis are combined [3–6]. Given the significantly strong antimicrobial effect of high-dose dual ALBC compared to low-dose single ALBC, it seems that the surgeons have also started to assess its effect in the clinical setting. In this review, we aimed to summarize the available in vitro and in vivo evidence that supports the notion that patients at a high risk of infection may benefit from the additional use of dual ALBC.

Risk factors for PJI and the idea of a risk-tailored local antibiotic prophylaxis with the aid of dual ALBC

Arthroplasty patients have different PJI risk profiles depending on the type of major comorbidities and the type of surgery. These patient factors increase the risk of infection but their percentage contributions are subject to the individual parameters. Several authors have found that body mass index (BMI) (in particular ≥35–40 kg/m²), uncontrolled diabetes, malnutrition, wound dehiscence, previous surgical site infections, and previous surgery were the dominant risk factors associated with a two- to five-fold higher incidence of PJI than “normal” [7–9]. Other major predictors of a higher PJI incidence include male gender, diabetes per se, post-traumatic arthritis, patellar resurfacing, and discharge to convalescent care [10]. These somehow heterogeneous findings may also explain why recently proposed PJI risk calculator tools [11] are still in the experimental stage. Nevertheless, these discussions serve to sensitize surgeons about the impact of the risk factors of PJI. In the future, they may also help implement a simple risk stratification algorithm in a given hospital instead of frequently encountered “intuition”-based handling of individual risk patients. Some specific procedures like revision surgery and hemi-arthroplasty are repeatedly described to be associated with several folds of high incidence of PJI. It is assumed that this is due to the longer operative time and the more invasive nature of revision procedures as well as to the surgeries on fragile patients in hemi-arthroplasty [12, 13].

Based on these observations, it has been hypothesized that a more risk-tailored antibiotic prophylaxis regimen may help mitigate the higher burden of PJI in these procedures. In principle, there are three options for modification of the standard antibiotic prophylaxis protocol: (1) extending the postoperative duration of antibiotic administration, e.g. beyond 24 h [14, 15]; (2) adding a second antibiotic to the standard perioperative systemic antibiotic prophylaxis regimen (e.g. vancomycin or teicoplanin to a cephalosporin) [16, 17]; and (3) in situ implant fixation with high doses and combinations of local antibiotics [18].

Although several reports from single study centers supported options 1 and 2 [14–17], neither tested modifications nor add-ons to the standard perioperative prophylaxis regimen show consistent advantages in a wider range of clinical studies so far [19]. Doubts remain as to whether the benefits outweigh the risks of extended antibiotic administration and antibiotic-mediated systemic side effects when two drugs are used in combination [20]. Therefore, some clinicians focus on reinforcement of the local antibiotic prophylaxis using dual ALBC, assuming a more powerful and more long-lasting antimicrobial effect in situ. Another advantage of this strategy is that the risk of toxic systemic levels is largely avoided if certain concentration thresholds are not exceeded [21, 22]. The idea of a reinforced local prophylaxis is based on the findings from laboratory studies. Dual ALBC loaded with combinations of gentamicin (G) and clindamycin (C) or combinations of gentamicin (G) and vancomycin (V) allow a high mutual release of antibiotics from the carrier matrix [23, 24]. It leads to a stronger and more long-lasting antimicrobial inhibition compared to a single low-dose antibiotic cement. Only the combinations of G+C and G+V in commercial bone cement brand COPAL® (Heraeus Medical, Wehrheim, Germany) were capable of preventing microbial growth of methicillin- and gentamicin-resistant staphylococci strains [25]. In contrast, gentamicin alone containing single ALBC brand PALACOS®+G (Heraeus Medical, Wehrheim, Germany) fails to do so. COPAL®G+C is superior to COPAL®G+V in bacterial inhibition (Fig. 1). These findings are clinically relevant given the increase in antibiotic resistance of these most relevant pathogens.
in PJI [26]. A recent report published by the same study group further described the antimicrobial effects of G + C and G + V combinations against Gram-negative bacteria, which are also described as important PJI pathogens. COPAL® G + C cement was found to exert the strongest antimicrobial effect against gentamicin-susceptible *Escherichia coli*, *Pseudomonas aeruginosa* or *Klebsiella pneumoniae*, presumably due to high concentration and elution of gentamicin in this dual ALBC combination (Fig. 1b) [27].

In addition to the commercial dual ALBC COPAL® G + C and COPAL® G + V brands, there are widespread non-standardized, off-label, and surgeon-directed antibiotic-cement mixtures in clinical use. Reasons for manually mixing antibiotics into bone cement include economic considerations, the lack of specific pre-mixed ALBC, limited local regulatory approvals, and the need to use specific customized solutions in septic revision arthroplasty. However, systematic biofilm inhibition data or clinical outcomes for such in-theatre admixed cement are not available. So, this review is limited to data compared to the commercial products.

Clinically meaningful stronger prophylactic effect of dual ALBC (COPAL® G + C)

Based on these promising in vitro data, the hypothesis of whether the dual ALBC protects high-risk patients better from infection than single ALBC was recently studied in clinical practice.

**Results from cemented hemi-arthroplasty patients**

In 2016, a proof of concept first showed that this strategy might positively impact on the incidence of surgical site infection and deep implant infection based on a quasi-randomized clinical trial including 848 femur fracture patients treated with cemented hemi-arthroplasty in the NHS Hospital Trust in the United Kingdom [28]. In this study, the patients were treated with either a single low-dose gentamicin cement (SALBC = PALACOS® + G) representing the current standard of care or dual high-dose antibiotic cement (DALBC = COPAL® G + C) as controls. They found the deep infection rates were significantly reduced from 3.5% (SALBC group) to 1.1% (DALBC group) (Fig. 2a). The rates of complications and side effects were similar in both groups. If we also consider the patients with superficial surgical site infection
in both groups, the difference between the groups is even more significant (1.7% in DALBC group vs. 5.3% in DALBC group) [28]. As a result of these findings, a multi-center, multi-surgeon, parallel, two-arm, randomized clinical trial (WHiTE 8 COPAL study) of approximately 5000 patients is now underway to consolidate the initial findings at a broader clinical level [29].

Results of septic vs. aseptic cemented revision

Septic revision: Jenny et al. [30] recently performed a retrospective study based on 171 patients undergoing one-stage septic revision. They found that DALBC (COPAL®G+C) cement was significantly associated with a lower risk of deep surgical site infection than SALBC (PALACOS®+G) two years after surgery (13 vs. 26%; odds ratio, 0.42) (Fig. 2b).

Aseptic revision: Sanz-Ruiz et al. [31] retrospectively reviewed 246 patients undergoing aseptic knee revision arthroplasty in a major university hospital in Madrid, Spain. One year after surgery, they found PJI a rate of 4.1% in 103 patients using SALBC (PALACOS®+G) and 0% in 143 patients using DALBC (COPAL®G+C), respectively (Fig. 2c). The authors concluded that the use of DALBC was a more potent and a cost-effective method for preventing infection [31].

Preliminary results from high-risk patients undergoing cemented primary arthroplasty

Sanz-Ruiz et al. [32] retrospectively studied 2,551 patients undergoing cemented primary arthroplasty between 2015 and 2018. Preoperatively, the patients were assessed based on the institution-specific patient risk algorithm (Fig. 3). In this series, 2,368 patients (92.8%) with low and high risks of infection were treated with SALBC (PALACOS®+G), and 183 patients (7.2%) with an exclusively high risk were treated with DALBC (COPAL®G+C). One year after surgery, the PJI rates were 3.7 and 2.45%, respectively (Fig. 2d). Contrary to expectations of a higher PJI rate in the exclusively high risk group they observed a trend to a lower PJI incidence if treated with DALBC.

Does use of high dose dual ALBC drive more antibiotic resistance?

This critical topic must be considered as surgeons have repeatedly expressed their concern that wider use of ALBC may promote antibiotic resistance. Usually, antibiotics are clinically selected based on the antibiogram that is determined in vitro by the susceptibility or resistance tests of bacteria at different dilutions. For systemic antibiotic therapies, the minimal inhibitory
concentration breakpoints are determined by both pharmacokinetic expectation of drug concentration in the tissues and the knowledge on minimal inhibitory concentrations (MIC) of the pathogen in vitro. However, such guidance is not available in local antibiotic therapies. Because the peak concentrations are often 10- to 100-fold higher than those reported in the systemic administration, susceptibility reporting criteria and minimal inhibitory concentration breakpoints are often not applicable to the local therapies [33]. Therefore, bacteria classified as intermediately resistant in the classical antibiogram may remain susceptible to high local concentrations of antibiotics, which is particularly true for antibiotics with bactericidal and strictly concentration-dependent effects, e.g., aminoglycosides. In view of these facts, induction of antibiotic resistance surrounding ALBC should not be a clinical concern. However, in the presence of a prior high-level aminoglycoside-resistant bacteria, survival and subsequent selection of these organisms may still occur, possibly even leading to recolonization in the carrier matrix [34].

Four recent studies addressed the question of whether the use of ALBC in a larger clinical setting increases bacterial antibiotic resistance in PJI. It was observed that its frequency was comparable in PJI patients regardless of whether their prostheses were cemented with ALBC or not [35–38]. One study went even further and looked at the resistance pattern of the few remaining gentamicin- and clindamycin-resistant bacteria in the PJI patients receiving cemented hemiprostheses with DALBC COPAL®G + C. The resistance to the antibiotics was limited, and there was no cross-resistance to the important therapeutic antibiotics, such as rifampin and quinolones [36]. These findings showed that the use of ALBC neither promotes widespread bacterial resistance nor affects the therapeutic options for those antibiotics recommended for the treatment of Gram-positive or Gram-negative pathogens in PJI.

Conclusions
Patients with multiple comorbidities and patients undergoing hemi- and revision arthroplasties are at a higher risk of developing PJI. Implementation of a risk-adapted antibiotic prophylaxis regimen in those patients is currently under clinical investigation. The use of high-dose DALBC may be an attractive option to decrease the risk of local infection by ensuring high peak concentrations and synergistic antimicrobial effects in situ. The preliminary clinical results support this hypothesis, showing that the incidence of PJI is reduced if the prostheses are cemented with DALBC in patients at high risk of infection. These benefits are not associated with more systemic side effects or high antimicrobial resistance. Further high-quality clinical studies are needed to consolidate these data on a broad clinical range.

Abbreviations
PJI: Prosthetic joint infection; PAP: Perioperative antibiotic prophylaxis; ALBC: Antibiotic-loaded bone cement; BMI: Body mass index; G: Gentamicin; C.
References
1. Antonelli B, Chen AF. Reducing the risk of infection after total joint arthroplasty: preoperative optimization. Arthroplasty. 2019;14. https://doi.org/10.1186/s42836-019-0003-7.
2. Siddiqi A, Forte SA, Docter S, Bryant D, Sheth NP, Chen AF. Perioperative antibiotic prophylaxis in total joint arthroplasty: a systematic review and meta-analysis. J Bone Joint Surg Am. 2019;101(9):828–42. https://doi.org/10.2106/JBJS.18.00990 PMID: 31045673.
3. Engesaeter LB, Espenhaug B, Lie SA, Furnes O, Havelin LI. Does cement increase the risk of infection in primary total hip arthroplasty? Revision rates in 56,275 cemented and uncemented primary THAs followed for 0–16 years in the Norwegian Arthroplasty Register. Acta Orthop. 2006;77(3):351–9. https://doi.org/10.1080/1745367060046253 PMID: 16819671.
4. Jamsen E, Huhtala H, Puolakka T, Moolanen T. Risk factors for infection after knee arthroplasty. A register-based analysis of 43,149 cases. J Bone Joint Surg Am. 2009;91(1):38–47. PMID: 19120207 https://doi.org/10.2106/JBJS.G10165 PMID: 19120207.
5. Jianek WA, Hansen AD, Greenwal AS. Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement. J Bone Joint Surg Am. 2006;88(11):2487–500. PMID: 17079409 https://doi.org/10.2106/JBJS.E.01126 PMID: 17079409.
6. Sanz-Ruiz P, Matas-Diez JA, Sanchez-Somolinos M, Villanueva-Martinez M, Vaquero-Martin J. Is the commercial antibiotic-loaded bone cement useful in prophylaxis and cost saving after knee and hip joint arthroplasty? Transatlantic Paradox J Arthroplasty. 2017;32(4):1095–9. https://doi.org/10.1016/j.arth.2016.11.012 Epub 2016 Nov 15 PMID: 27919578.
7. Lenguerrand E, Whitehouse MR, Backwell AD, Kunustor SK, Burston B, Porter M, Blom AW. Risk factors associated with revision for prosthetic joint infection after hip replacement: a prospective observational cohort study. Lancet Infect Dis. 2018;18(9):1004–14. https://doi.org/10.1016/S1473-3099(18)30345-1 Epub 2018 Jul 25. PMID: 30056097; PMCID: PMC6105575.
8. Lenguerrand E, Whitehouse MR, Backwell AD, Kunustor SK, Fouquet P, Porter M, Blom AW. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. Risk factors associated with revision for prosthetic joint infection following knee replacement: an observational cohort study from England and Wales. Lancet Infect Dis. 2019;19(6):589–600. https://doi.org/10.1016/S1473-3099(18)30355-2 Epub 2019 Apr 17. PMID: 31005559; PMCID: PMC6531378.
9. Kunustor SK, Whitehouse MR, Blom AW, Backwell AD, INFORM Team. Patient-related risk factors for periprosthetic joint infection after total joint arthroplasty: a systematic review and meta-analysis. PLoS One. 2016;11(3):e0150866. https://doi.org/10.1371/journal.pone.0150866 PMID: 26938768; PMCID: PMC4777569.
10. McMaster Arthroplasty Collaborative (MAC). Incidence and predictors of prosthetic joint infection following primary total knee arthroplasty: a 15-year population-based cohort study. J Arthroplasty. 2022;37(2):367–372.e1. https://doi.org/10.1016/j.arth.2021.10.006 Epub 2021 Oct 20. PMID: 34678445.
11. Tan TL, Maltenfort MG, Chen AF, Shiha A, Higuera CA, Siqueira M, Parvizi J. Development and evaluation of a preoperative risk calculator for periprosthetic joint infection following total joint arthroplasty. J Bone Joint Surg Am. 2018;100(9):777–85. https://doi.org/10.2106/JBJS.16.01435 PMID: 29715226.
12. Quinlan ND, Werner BC, Brown TE, Browne JA. Risk of prosthetic joint infection increases following early aseptic revision surgery of total hip and knee arthroplasty. J Arthroplasty. 2020;35(12):3661–7. https://doi.org/10.1016/j.arth.2020.06.089 Epub 2020 Jul 3 PMID: 32712119.
13. Gallardo-Calero I, Larainzar-Coghein T, Rodriguez-Pardo D, Pignau C, Sanchez-Raya J, Amat C, Lung M, Carrera L, Corona PS. Increased infection risk after hip hemiarthroplasty in institutionalized patients with proximal femur fracture. Injury. 2016;47(4):872–6. https://doi.org/10.1016/j.injury.2015.12.032 Epub 2016 Jan 7 PMID: 26857632.
14. Inabathula A, Dilley JE, Zimba-Davies M, Warth LC, Azzam KA, Ireland PH, Meneghini RM. Extended oral antibiotic prophylaxis in high-risk patients substantially reduces primary total hip and knee arthroplasty 90-day infection rate. J Bone Joint Surg Am. 2018;100(24):2103–9. https://doi.org/10.2106/JBJS.17.01485 PMID: 30562290.
15. Clare G, Tornero E, Martinez-Pastor JC, Piauvelo M, Martinez J, Bosch J, Mensa J, Soriano A. A prolonged post-operative antibiotic regimen reduced the rate of prosthetic joint infection after aseptic revision knee arthroplasty. Surg Infect (Larchmt). 2015;16(6):775–80. https://doi.org/10.1089/sur.2015.044 Epub 2015 Aug 4 PMID: 26241469.
16. Sewick A, Makani A, Wu C, O’Donnell J, Baldwin KD, Lee GC. Does dual antibiotic prophylaxis better prevent surgical site infections in total joint arthroplasty? Clin Orthop Relat Res. 2012;470(10):2702–7. https://doi.org/10.1007/s11999-012-2255-1 PMID: 22921030.
17. Tornero E, Garcia-Ramiro S, Martinez-Pastor JC, Bori G, Bosch J, Morata L, Sala M, Basora M, Mensa J, Soriano A. Prophylaxis with teicoplanin and cefozoxime reduces the rate of prosthetic joint infection after primary arthroplasty. Antimicrob Agents Chemother. 2015;59(2):831–7. https://doi.org/10.1128/AAC.03949-14 Epub 2014 Nov 17 PMID: 25043662; PMCID: PMC4335835.
18. Berberich CE, Josse J, Laurenz F, Ferry T. Dual antibiotic-loaded bone cement in patients at high infection risks in arthroplasty: rationale of use for prophylaxis and scientific evidence. World J Orthop. 2021;12(3):119–28. https://doi.org/10.5312/wjo.v12.i3.119 PMID: 33816139; PMCID: PMC7995542.
19. Veitmann ES, Lenguerrand E, Moeen JDF, Whitehouse MR, Nellissen RGHH, Blom AW, Poolman RW. Similar risk of complete revision for infection with single-dose versus multiple-dose antibiotic prophylaxis in primary arthroplasty of the hip and knee: results of an observatiotional cohort study in the Dutch Arthroplasty Register in 242,179 patients. Acta Orthop.
2020;591(6):794–800. https://doi.org/10.1007/s00167-020-17940-96
Epub 2020 Jul 23. PMID: 32698642; PMCID: PMC6023957.
20. Courtney PM, Melnic CM, Zimmer Z, Anari J, Lee GC. Addition of vanco-
mycin to cefazolin prophylaxis is associated with acute kidney injury after
primary joint arthroplasty. Clin Orthop Relat Res. 2015;473(7):2197–203.
https://doi.org/10.1007/s11999-014-4062-3 PMID: 25421958; PMCID:
PMC4547775.
21. Oe K, Iida H, Ueda N, Nakamura T, Okamoto N, Ueda Y. In vivo serum
concentration of vancomycin in antibiotic-acrylic bone cement for the
prevention and treatment of periprosthetic hip infection. J Orthop Sci.
2017;22(4):710–4. https://doi.org/10.1007/s00776-017-0303-3 PMID:
28342695.
22. Dagneaux I, Limberg AK, Osmon DR, Leung N, Berry DJ, Abdel MP. Acute
kidney injury when treating periprosthetic joint infections after total
knee arthroplasties with antibiotic-loaded spacers: incidence, risks, and
outcomes. J Bone Joint Surg Am. 2021;103(9):754–60. https://doi.org/10.
2106/JBJS.20.01828 PMID: 33780403.
23. Kuehn KD, Ege W, Gopp U. Acrylic bone cements: composition and
properties. Orthop Clin North Am. 2005;36(1):17–28, v. https://doi.org/10.
1016/j.jocn.2004.06.010 PMID: 15542119.
24. Ensing GT, van Horn JR, van der Mei HC, Busscher HJ, Neut D. Copal
bone cement is more effective in preventing biofilm rejection than
Palacos R-G. Clin Orthop Relat Res. 2008;466(6):1492–8. https://doi.org/
10.1007/s11999-008-0203-x Epub 2008 Mar 13. PMID: 1838216; PMCID:
PMC2384043.
25. Cara A, Ballet M, Hemery C, Ferry T, Laurent F, Josse J. Antibiotics in bone
implants for the WHiTE 8 COPAL study. Bone Jt Open. 2021;2(2):72–8. https://
doi.org/10.1007/s11999-021-06649-x. PMID: 33553196; PMCID: PMC78568.
26. Molina-Manso D, del Prado G, Ortiz-Pérez A, Manrubia-Cobo M, Gómez-
Barrena E, Cordero-Ampeuro J, Esteban I. In vitro susceptibility of
Staphylococcus aureus and Staphylococcus epidermidis prosthetic joint infection.
Front Med (Lausanne). 2021;20(7).576231 PMID: 33553196; PMCID: PMC78568.
27. Cara A, Ferry T, Laurent F, Josse J. Prophylactic antibiofilm activity of
antibiotic-loaded bone cement against gram-negative bacteria. Antibiot-
cics. 2022;11:137. https://doi.org/10.3390/antibiotics11102013760.
28. Sprowson AP, Jensen C, Chambers S, Parsons NR, Aradhhyula NM, Carluke
I, Inman D, Reed MR. The use of high-dose dual-impregnated antibiot-
cement does not increase antibiotic resistance after primary total joint
arthroplasty. Clin Orthop Surg. 2020;12(3):318–23. https://doi.org/
10.1007/s11999-020-00182-5 PMID: 33748827.
29. Agni NR, Costa ML, Achten J, O’Connor H, Png ME, Peckham N, Dutton
SJ, Wallis S, Milca S, Reed M. A randomized clinical trial of low dose
single antibiotic-loaded cement versus high dose dual antibiotic-loaded
cement in patients receiving a hip hemiarthroplasty after fracture: a pro-
tocol for the WHiTE 8 COPAL study. Bone Joint J. 2021;103(2):72–8.4
https://doi.org/10.7150/bjbj.22192 PMID: 3013893; PMCID: PMC6043471.
30. Hansen EN, Adelli B, Kenyon R, Parvizi J. Routine use of antibiotic
laden bone cement for primary total knee arthroplasty: impact on
infecting microbial patterns and resistance profiles. J Arthroplasty.
2014;29(6):1123–7. https://doi.org/10.1016/j.arth.2013.12.004 Epub 2013
Dec 10 PMID: 24418770.
31. Tootsi K, Heesen V, Lohrengel M, Enz AE, Illiger S, Mittelmeier W, Lohmann
CH. The use of antibiotic-loaded bone cement does not increase anti-
biotic resistance after primary total joint arthroplasty. Knee Surg Sports
Traumatol Arthrosc. 2021. https://doi.org/10.1007/s00167-021-06649-x. Epub
ahead of print. PMID: 34244827.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.